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ABSTRACT
Tumor-angiogenesis is the multi-factorial process of sprouting of endothelial cells 
(EC) into micro-vessels to provide tumor cells with nutrients and oxygen. To explore 
miRNAs as therapeutic angiogenesis-inhibitors, we performed a functional screen to 
identify miRNAs that are able to decrease EC viability. We identified miRNA-7 (miR-7) 
as a potent negative regulator of angiogenesis. Introduction of miR-7 in EC resulted 
in strongly reduced cell viability, tube formation, sprouting and migration. Application 
of miR-7 in the chick chorioallantoic membrane assay led to a profound reduction 
of vascularization, similar to anti-angiogenic drug sunitinib. Local administration 
of miR-7 in an in vivo murine neuroblastoma tumor model significantly inhibited 
angiogenesis and tumor growth. Finally, systemic administration of miR-7 using a 
novel integrin-targeted biodegradable polymeric nanoparticles that targets both EC 
and tumor cells, strongly reduced angiogenesis and tumor proliferation in mice with 
human glioblastoma xenografts. Transcriptome analysis of miR-7 transfected EC in 
combination with in silico target prediction resulted in the identification of OGT as 
novel target gene of miR-7. Our study provides a comprehensive validation of miR-
7 as novel anti-angiogenic therapeutic miRNA that can be systemically delivered to 
both EC and tumor cells and offers promise for miR-7 as novel anti-tumor therapeutic. 
INTRODUCTION
Angiogenesis, the de novo formation of blood 
vessels from pre-existing vasculature, is not only a 
physiological process but also a driving factor in many 
pathologies [1]. Physiological angiogenesis is essential 
both during development and in adulthood, for example 
during wound healing and in the female reproductive 
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system [2]. Angiogenesis occurs locally and is self-
limited in time [3]. In contrast, pathological angiogenesis 
is often chronic and manifests in autoimmune diseases, 
age-related macular degeneration, atherosclerosis and 
cancer [3]. In many cancers angiogenesis is required 
for tumor progression: when the volume of a malignant 
mass becomes larger than several cubic millimeters, the 
increasing demand for nutrients and oxygen induces the 
production of angiogenic growth factors [4, 5]. Binding 
of these growth factors to receptors on nearby quiescent 
endothelial cells (EC) in pre-existing capillaries, leads to 
their activation, proliferation and ultimately formation of 
new vessels [6]. 
The critical role of angiogenesis in cancer 
progression has been validated clinically, and exploited 
therapeutically. Current anti-angiogenic therapeutics have 
shown clinical benefit for several cancer indications, but 
improvement in overall survival scores is minimal in many 
others [7, 8]. In addition, the development of resistance 
against anti-angiogenic single pathway therapies allows 
tumor re-growth due to activation of alternative pathways 
and remains a significant challenge for the treatment of 
cancer [9]. 
miRNAs are naturally occurring non-coding small 
double stranded RNA molecules of approximately 22 
nucleotides in length, which are now established as 
important regulatory factors of gene expression in multiple 
pathways [10]. Recently their endogenous role has been 
shown to apply to angiogenesis [11, 12]. The first miRNA 
involved in angiogenesis was identified by Wurdinger et 
al. [13] and many others followed [14-19]. The ability 
of miRNAs to regulate multiple genes underlying 
angiogenesis provides exciting new opportunities for 
targeted anti-angiogenic therapy. Uniquely, miRNAs may 
combine broad anti-angiogenic activity against multiple 
targets with a presumed attractive toxicity profile since 
these miRNAs are also naturally expressed in normal 
tissue. 
In the present study, a human miRNA lentiviral-
based expression library encoding novel and known 
miRNAs [20] was screened in EC. miRNAs that inhibit 
proliferation of human primary EC and immortalized 
vascular EC were identified. The most potent miRNA, 
miR-7, was validated for anti-angiogenic activity 
in vitro. This miRNA was further validated in vivo 
with a chorioallantoic membrane (CAM) assay and 
a subcutaneous murine tumor model using local 
administration and electroporation. With strong support 
for its potential as an anti-angiogenic therapeutic agent, 
a clinically viable formulation which is based on a novel 
integrin targeted polymer-biodegradable nanoparticles 
delivery system, was used for intravenous administration. 
Delivery of miR-7 using this novel formulation 
demonstrated inhibition of tumor growth in a human 
glioblastoma xenograft model. 
RESULTS
Identification of anti-angiogenic miRNA using a 
lentiviral based miRNA library
We aimed to identify miRNAs with a regulatory role 
in angiogenesis by screening a lentivirus-based expression 
library of 1120 human miRNAs. Viability of primary 
(HUVEC) and immortalized EC (EC-RF24) was assessed 
in a primary high throughput screen after infection of the 
cells. Initially, we identified 110 candidate miRNAs with 
either inhibitory or stimulatory effect on endothelial cell 
(EC) growth, of which 41 were confirmed in a secondary 
screen (Supplementary Fig. S1 and Table S1 for more 
details). In general the anti- and pro-proliferative activity 
of the lentivirus-expressed miRNAs was more pronounced 
in HUVEC than in EC-RF24 cells. In this study we 
focused on inhibitory miRNAs because the number of 
inhibitory hits was larger and the efficacy of the inhibitory 
hits on cell viability was larger than with stimulatory 
hits (see Table S1). To further narrow down to the most 
potent inhibitory miRNAs, our final selection consisted 
Table 1: Final list of six endothelial anti-proliferative pre-miRNA from the lentiviral 
library in HUVEC and EC-RF24. Results are shown as % of viable cells compared to 
Empty Vector controls using MTS-read-out. (See Supplementary Fig. S1 and Table S1 for 
more detail)
% of viability (MOI 100) % of viability (MOI 200)
Lentivirus HUVEC  EC-RF24 HUVEC  EC-RF24 
hsa-miR-7-3 45 53 41 43
hsa-miR-142 52 88 46 81
hsa-miR-26b 60 72 53 57
hsa-miR-574 61 93 60 98
hsa-miR-9-2 61 85 56 65
hsa-miR-190b 63 75 58 72
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of miRNAs with >35% inhibitory effect in HUVEC 
(Table 1). Among the 6 selected miRNAs, hsa-miR-7-3 
demonstrated the strongest anti-proliferative effect. The 
sequence of the hsa-miR-7-3 lentivirus was confirmed 
by Sanger sequencing. Stem-Loop RT-PCR showed that 
the pre-miRNA-7 hairpin is processed into mature miR-
7 (hsa-miR-7-5p, Supplementary Table S2). We therefore 
selected miR-7 for further validation as an anti-angiogenic 
miRNA candidate. 
Anti-angiogenic activity of miR-7 mimic in vitro
The anti-angiogenic activity of miR-7 was first 
studied by testing the anti-proliferative activity of 
a synthetic mimic of miR-7 in HUVEC at different 
Figure 1: Anti-angiogenic property of miR-7 in vitro. (a) miR-7 inhibits HUVEC cell viability. Cell viability was measured at 72 
hrs after transfection using MTS-read-out. Cells were transfected with increasing concentrations of miR-7, miR-scr or siPLK-1. siPLK-1 
and miR-scr were used as positive and negative control. Data are normalized to cell viability of untreated cells and plotted as mean values ± 
s.d. (n=3). (b) Cellular miR-7 expression increases after transfection of HUVEC with increasing concentrations of miR-7. miR-7 expression 
was measured by stem-loop RT-PCR at 72 hrs after transfection. Data are normalized to untreated cells and plotted as mean values ± s.d. 
(n=3), * p<0.001. (c-d) miR-7 inhibits two-dimensional tube formation. HUVEC were transfected with 50 nM miR-7 or miR-scr and 
seeded on matrigel at 48hrs after transfection. Pictures were taken at 17 hrs after seeding (magnification in Supplementary Fig. S11). Two-
dimensional tube-formation was quantified by counting number of branching points and calculating the cumulative length of the tube of 
each image. Data are plotted as mean values ± s.d. (n= 3), * p<0.0001. (e-f) miR-7 inhibits three-dimensional sprouting. HUVEC were 
transfected with 50 nM miR-7 or miR-scr. 24hrs after transfection cell-spheroids were embedded in a collagen matrix in the presence of 
basic Fibroblast Growth Factor (bFGF). Untreated HUVEC in the absence of bFGF were used as negative control and the sprouting of 
miR-7 and miR-scr treated cells were compared to the sprouting of bFGF activated HUVEC. Pictures were taken at 16 hrs after embedding. 
Three-dimensional sprouting was quantified by counting the sprouts and calculating the cumulative length of 10 individual spheroids for 
each treatment. Data are plotted as mean values ± s.d. (n= 10), * p<0.0001. (g-h) miR-7 inhibits migration. HUVEC were transfected 
with 50 nM miR-7 or miR-scr. Cells were harvested at 48hrs after transfection and equal amount of cells were seeded in 24-well plate and 
wounded by a scratch. Images were taken right after the wound scratch (T=0) and at 17hrs after scratching (T=17) Wound closure was 
quantified by calculating unclosed surface area relative to surface area right after the scratch wound. Data are plotted as mean values ± s.d. 
(n=3),* p<0.001.
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concentrations (Fig. 1a). After transfection of HUVEC 
with miR-7 mimic cell proliferation was inhibited in a 
concentration dependent manner, up to 50% inhibition 
compared to a negative control miRNA with a scrambled 
sequence (miR-Scr). To confirm that transfection of 
HUVEC with increasing concentrations of miR-7 mimic 
led to increasing intra-cellular levels of miR-7, intra-
cellular levels of miR-7 were measured by stem loop RT-
PCR (Fig. 1b). The anti-proliferative effect of miR-7 was 
comparable to that of a positive control, i.e. siRNA against 
Polo-like kinase 1 (Plk1), a cell proliferation kinase. 
The anti-proliferative activity of miR-7 was confirmed 
in a BrdU cell proliferation assay (Supplementary Fig. 
S2a). Caspase-3 cleavage in HUVEC treated with miR-7 
suggests that part of the anti-proliferative activity results 
in cell apoptosis (Supplementary Fig. S2b). To investigate 
whether miR-7 also affects EC tube formation and 
sprouting, HUVEC were transfected with miR-7 mimic, 
seeded on Matrigel at low density, and the formation of 
tubules in presence of growth factors was characterized 
(Fig. 1c). The results showed a statistically significant 
reduction in the number of branching points and 
cumulative tube length compared to the negative controls 
by approximately 76% and 90%, respectively (Fig. 1d). 
Similarly, a three-dimensional collagen based spheroid 
assay showed that transfection of EC with the miR-7 
mimic resulted in a statistically significant reduction in 
the number of sprouts and cumulative sprout length of 
EC by approximately 47% and 62%, respectively (Fig. 1e 
and f). Since EC migration also plays an important role in 
angiogenesis, the effect of miR-7 mimic on wound closure 
was studied in an EC scratch assay (Fig. 1g). Indeed, miR-
7 inhibited wound closure while miR-Scr transfected cells 
did not (Fig. 1h). 
Gene modulation by miR-7 mimic – HUVEC 
culture
One of the hallmarks of miRNAs is their ability to 
target and regulate multiple genes. To explain the anti-
angiogenic properties of miR-7, gene expression analysis 
was performed using RNA-seq. Differential expression 
analysis showed that 2500 genes were significantly up- or 
downregulated after transfection of HUVEC with miR-7 
mimic (p-value < 0.05, compared to miR-Scr, Fig. 2a). The 
majority, 1317, of the miR-7 modulated genes were down-
regulated while 1183 were upregulated. Comparison of the 
list of down-regulated genes with a list of 11 clinically 
explored molecular targets in angiogenesis (Table 2) 
showed that eight genes matched the clinical target list. 
For each of these “therapeutic targets”, compounds are 
presently in clinical development (Table 2). The complete 
gene expression profile was analyzed using Ingenuity 
Pathway Analysis software (IPA). First, the set of regulated 
genes was overlaid with the 1051 predicted miR-7 targets, 
based on the TargetScan prediction tool in IPA. In total 
282 predicted miR-7 targets were up- or downregulated 
within the set of 2500 genes (Fig. 2b). Consistent with the 
mechanism that miRNA down-regulate mRNA expression, 
264 predicted targets (94%) were downregulated while 
only 18 (6%) were upregulated. 
IPA was also used to identify biological processes 
that are regulated by miR-7 (Supplementary Table S3). 
Genes involved in functions associated with cell death 
and apoptosis were increased, while genes involved 
Table 2: miR-7 mediated differential expression of genes that are currently clinically explored as 
anti-angiogenic drug targets. The log2(ratio) was calculated as described in Material and Methods 
and reflects the differential expression of genes in HUVEC treated with miR-7 and gene expression in 
HUVEC treated with miR-Scr. Eight out of 11 genes that are associated to novel anti-angiogenic drugs 
are down regulated
Genes highly involved in 
tumor angiogenesis
Expression ratio after miR-
7 treatment versus control 
(log2(ratio))
Example of drug in clinical trial
VEGF-B 1.443 Aflibercept (Regeneron)
VEGF-C -0.778 VGX-100 (Circadian)
Angiopoeitin-2 -0.805 PF-04856884 (Pfizer)
PDGF-D 0.899 CR-002 (CuraGen)
Jagged-1 -0.739 RO4929097 (Roche)
ADAM-10 -0.870 INCB3619 (InCyte)
FGF-2 -1.732 Gal-F2 (Galaxy/Roche)
CXCR4 1.169 BMS-936564 (Bristoll Myers Squibb)
S1PR1 -1.108 Fingolimod (Novartis)
S1PR3 -1.035 Fingolimod (Novartis)
NRP1 -0.801 MNRP1685A (Genentech) antibody
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in functions such as cell migration, proliferation and 
vasculogenesis were decreased. Overlay of strongly 
down-regulated angiogenesis-associated genes (log2 ratio 
(miR-7 vs. miR-Scr), p-value <0.05) with predicted miR-
7 targets (Supplementary Table S4) pointed to O-linked 
β-N-acetylglucosamine transferase (OGT) as potentially 
important mediator of miR-7 action. OGT is an enzyme 
that adds O-linked β-N-acetylglucosamine (O-GlcNAc) 
moieties to various nuclear and cytosolic proteins and 
gained interest as anti-tumor therapeutic target in recent 
years [21, 22]. The observed downregulation of OGT in 
miR-7 transfected HUVEC was confirmed by RT-PCR 
and Western Blot analysis over a concentration range of 
15-100 nM (Fig. 2c and d). To proof that OGT is a direct 
target gene of miR-7, we measured luciferase activity in 
Hela cells transfected with a plasmid containing the 3′UTR 
sequence of OGT. The decrease in luciferase activity in the 
presence of miR-7 indicates a direct interaction between 
miR-7 and the 3′UTR of OGT (Fig. 2e). Mutagenesis of 
the 3′UTR sequence of the predicted binding site of miR-
7 (Fig. 2f) restored luciferase activity, thereby confirming 
the specificity of the interaction between miR-7 and the 
OGT 3′UTR (Fig. 2e). To study the effect of OGT on 
angiogenesis, RNA interference was used to inhibit OGT 
expression in EC. As additional positive control Alloxan 
was used, which is a well known small molecule OGT 
inhibitor [23]. Both siRNA against OGT and Alloxan did 
not inhibit EC migration or EC tube formation in vitro, 
suggesting that OGT is a good marker gene of miR-7, 
but not the prime miR-7 target through which EC cell 
Figure 2: miR-7 modifies endothelial gene expression. (a) miR-7 changes the expression of 2500 HUVEC genes after transfection. 
HUVEC were transfected with either miR-7 or miR-Scr and the transcriptome was quantified by RNA-Seq. All differentially expressed 
genes, which are statistically significant down- or upregulated compared to miR-Scr (p-value< 0.05) are plotted. (b) Majority of miR-7 
predicted target genes are downregulated. Differentially expressed genes that are regulated by miR-7 and are a predicted target genes of 
miR-7 are plotted. (c) mRNA expression of OGT is downregulated after miR-7 transfection. HUVEC were transfected with increasing 
concentrations of miR-7 or miR-Scr. OGT expression was measured by RT-PCR at 48 hrs after transfection. Data are normalized to 
untreated cells and plotted as mean values ± s.d. (n=3), *p<0.001. (d) OGT protein is downregulated after miR-7 transfection. HUVEC 
were transfected with increasing concentration of miR-7 or miR-Scr. OGT expression was determined by Western Blot analysis at 48 hrs 
after transfection. Beta-Actin was used as an internal control. (e) OGT is a target gene of miR-7. Luciferase activities in Hela cells co-
transfected with a luciferase- OGT 3′UTR plasmid containing either wildtype (WT) 3′UTR or mutated sequence and either miR-Scr or 
miR-7 at 24 hrs post transfection. Data are normalized to miR-Scr and plotted as mean values ± s.d. (n=3), *p<0.0002. (f) Alignment of 
miR-7 and OGT sequence. Mutations were generated on the potential target sequence (horizontally underlined).
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migration and tube formation are inhibited (Supplementary 
Fig. S3 and S4). 
Anti-angiogenic activity of miR-7 mimic in vivo– 
chick CAM assay
Mature miR-7 is conserved between chicken, 
human, and mouse (Fig. 3a). This streamlines translation 
of our in vitro data to in vivo tests for anti-angiogenic 
activity, starting with local treatment in a chick 
chorioallantoic membrane (CAM) assay (Fig. 3b). A 
reduction in vascular density in the regions between large 
blood vessels was visible in CAM treated with miR-7 
mimic while vascular density was not reduced in untreated 
or miR-Scr treated CAM (Fig. 3b). This is indicative of 
a strong anti-angiogenic activity of miR-7. This was 
supported by the observation that treatment of CAM 
with a clinically approved multikinase anti-angiogenic 
drug, sunitinib, showed a similar inhibitory effect on 
vascularization. 
Anti-angiogenic activity of miR-7 mimic in vivo– 
local tumor administration 
Based on the potent anti-angiogenic activity of miR-
7 observed both in vitro and in vivo in the CAM assay, 
the anti-angiogenic potency and inhibitory effect on tumor 
growth was investigated in a subcutaneous neuroblastoma 
(N2A) mouse tumor model using intratumoral injections 
and electroporation. The miR-7 mimic (10 µg) treated 
mice exhibited a 43% reduction in tumor growth compared 
to both the PBS and miR-Scr negative control treated 
mice (Fig. 4a). Stem-loop RT-PCR was used to determine 
the relative tumor amounts of miR-7 in the different 
treatment groups. Tumors of miR-7 treated animals 
showed significantly higher miR-7 levels compared to 
the control groups (Fig. 4b). The biochemical process 
underlying tumor growth inhibition by miR-7 mimics was 
investigated using immunohistochemical (IHC) detection 
of CD31, an endothelial cell marker for microvessel 
density (Fig. 4c). MiR-7 mimic treated tumors displayed a 
reduced microvessel density, indicative of anti-angiogenic 
activity of the treatment (Fig. 4d). However, no differences 
in expression of Ki-67, a marker for proliferation, were 
detected among the treatment groups (Fig. 4e and f). 
These data suggest that inhibition of angiogenesis is the 
prime mechanism for the N2A tumor growth suppression 
upon intratumoral delivery of miR-7. The lack of efficacy 
on tumor cell proliferation in vivo is corroborated by the 
observation that miR-7 did not inhibit cell viability of 
N2A cells in vitro (Supplementary Fig. S5). 
Anti-angiogenic activity of miR-7 mimic in vivo– 
systemic tumor neovasculature targeting 
Clinical application of miRNA-based therapeutics 
is dependent on systemic administration and intracellular 
delivery of the miRNA (mimic) to the target site. Studies 
have shown an ability of cRGD-targeted nanoparticles 
to provide neovasculature targeting and VEGF pathway 
siRNA inhibition of angiogenesis in murine models [24-
26]. Therefore, this approach was selected for systemic 
Figure 3: Effect of miR-7 on the CAM-assay. (a) Seed sequence of miR-7. Illustration of conserved seed sequence of miR-7 among 
different species. (b) miR-7 acts as vascular disrupting agent on CAM. Chick CAMs were treated locally within a nitrocellulose ring with 
300 picomol miR-7 or miR-Scr using Lipofectamine 2000 or with 200 picomol sunitinib. Untreated and mock treated CAM were used as 
controls. Representative photographs were taken prior to transfection (T=0) and at 48 hrs after transfection (T=48). 
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delivery of miR-7. Hereto, a novel biodegradable 
neovasculature targeted nanoparticles formulation was 
developed and used to investigate the anti-tumor activity 
of miR-7 following intravenous administration in human 
glioblastoma U-87 MG bearing mice. U-87 MG tumor 
bearing mice were treated with miR-7 mimic using a 
cyclic Arginine-Glycine-Aspartic acid (cRGD) peptide 
coupled biodegradable polyamide nanoparticles, targeting 
integrins αvβ3 and αvβ5. These integrins are present on 
tumor EC neovasculature, as well as on certain tumor 
cells [27], such as observed with the U-87 MG tumor cell 
line (Supplementary Fig. S6). The results demonstrate 
that targeted systemic delivery of miR-7 inhibited tumor 
angiogenesis and growth. Tumors of the miR-7 treatment 
group were pale and less vascularized compared to those 
in control groups (Fig. 5a) and systemic delivery of miR-7 
mimic inhibited tumor growth by 42% after two weeks of 
treatment (Fig. 5b). The anti-angiogenic property of miR-
7 was also observed microscopically with a statistically 
significant reduction of immunohistochemical staining 
of CD31 in tumor tissue from the miR-7 treated mice 
(Fig. 5c and d). Moreover, tumor tissue from the miR-7 
treated mice contained considerable amounts of necrotic 
lesions, which is an indication of hypoxia from reduced 
angiogenesis. Systemic delivery of miR-7 mimic not 
only reduced tumor angiogenesis but also reduced tumor 
proliferation as demonstrated by the statistically significant 
reduction in Ki-67 staining of miR-7 treated tumor tissue 
(Fig. 5e and f). This was confirmed by in vitro studies 
that demonstrated reduced proliferation of U-87 MG cells 
upon transfection with miR-7 mimic (Supplementary 
Fig. S7). To confirm effective delivery of miR-7 into the 
tumor tissue we performed IHC staining of OGT, one of 
the target genes of miR-7 (Fig. 5g). miR-7 treated mice 
showed a statistically significant reduction in OGT levels 
(Fig. 5h). Downregulation of OGT by miR-7 is not EC 
Figure 4: Inhibitory effect of miR-7 on tumor growth by local delivery. (a) miR-7 inhibits tumor growth after local delivery. 
AJ mice bearing tumors with Neuro2A cells were treated locally with 10 µg miR-7 or 10 µg miR-Scr or PBS by intratumoral injection and 
electroporation. Arrows below the graph indicate treatment schedule (6 treatments , every other day). Data are plotted as mean values ± 
SEM (n=7), p<0.05. (b) Increased presence of miR-7 in miR-7 treated animals. The day after the last injection tumors were removed and 
total RNA was isolated. Delivery of miR-7 by electroporation into the tumor tissue was determined by stem loop RT-PCR. Values were 
normalized to U6 expression in the tumors. Data are plotted as mean values ± s.d. (n=3), *p<0.001. (c-d) miR-7 reduces angiogenesis in 
vivo after local delivery. Tumor sections were stained for CD31 (in brown) and microvessel density (MVD) was quantified by counting 
blood vessels in 6 random high magnification fields in each sample. Data are plotted as mean values ± s.d. (n=4), *p< 0.01. (e-f) miR-7 does 
not affect proliferation in Neuro2A tumors. The effect of miR-7 on tumor cell proliferation was determined by Ki-67 staining (in brown). 
Quantification of the images was performed in the same way as described in (c-d), and expressed as percentage of the PBS treated group. 
Data are plotted as mean values ± s.d. (n=4). Magnification of Fig 4c and 4e in Supplementary Fig. S12.
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specific, but was also confirmed in U-87 MG cells in vitro 
(Supplementary Fig. S8). The observed inhibition of tumor 
growth can thus be ascribed to a combination of an anti-
angiogenic effect of miR-7 delivered to tumor-associated 
EC and an anti-proliferative effect of miR-7 delivered to 
tumor cells. Similar to EC, downregulation of OGT in 
U-87 MG cells by RNAi interference did not inhibit cell 
viability (Supplementary Fig. S9), indicating that also in 
tumor cells OGT is a good marker for miR-7 delivery but 
not for miR-7 efficacy. 
DISCUSSION
This study has identified miR-7 as a prominent 
Figure 5: Inhibitory effect of miR-7 on tumor growth by systemic delivery. (a) miR-7 treated animals show pale and less 
vascularized tumors. Macroscopic images of the tumors after the 7th dose administration. (b) miR-7 inhibits tumor growth after systemic 
delivery. Athymic Nude-Foxn1nu mice bearing U-87 MG tumors were injected intravenously with αvβ3/ αvβ5 targeted miR-7 nanoparticles 
(3 mg/kg miRNA). Arrows in the graph indicate the days of treatment (8 treatments, every other day). miR-7 treated mice showed 
significant tumor growth inhibition compared to vehicle treated mice. Data are plotted as mean values ± SEM (n=10), *p<0.05. (c-d) miR-7 
reduces angiogenesis after systemic delivery. Tumor sections were stained for CD31 (in brown) and quantified by counting CD31 positive 
staining area (pixels) in 6 random fields in each tumor. Data are plotted as mean values ± s.d. (n=5), *p<0.001. Magnification of Fig 5c 
in Supplementary Fig. S13. (e-f) miR-7 reduces cell-proliferation in U-87 MG tumors after systemic delivery. Anti-proliferative effect 
of systemically delivered miR-7 was determined by Ki-67 staining, indicated as brown spots. Quantification of Ki-67 was performed by 
counting of the stains in 6 random fields in each tumor section and proliferation was expressed as percentage of PBS treated mice. Data 
are plotted as mean values ± s.d. (n=5), *p<0.001. (g-h) miR-7 reduces OGT in U-87 MG tumors after systemic delivery. Tumor sections 
stained for OGT (brown nuclei and brownish cytoplasm) and quantified by counting of the stains in 6 random fields in each tumor section. 
Data are plotted as mean values ±s.d. (n=5), * p=0.0004.
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regulator of angiogenesis. In a functional screen with 
a lentiviral miRNA library miR-7 was identified as 
inhibitor of EC proliferation. The anti-angiogenic 
property of lentivirally expressed miR-7 was confirmed 
by investigating the efficacy of miR-7 synthetic mimics 
in multiple in vitro angiogenesis assays, each focusing 
on different hallmarks of angiogenesis. MiR-7 not only 
inhibited EC proliferation by 50%, but also inhibited 
migration of EC by nearly 70%. In more complex in 
vitro angiogenesis assays, miR-7 inhibited the ability of 
HUVEC to form two-dimensional tubules on matrigel 
and three-dimensional sprouts in collagen. Together, these 
studies demonstrate strong anti-angiogenic activity of 
miR-7 upon overexpression in EC. In earlier studies, miR-
7 was not picked up as miRNA involved in angiogenesis in 
an EC specific differential expression screen (13), which 
may suggest that miR-7 has no physiological role in EC to 
regulate angiogenesis. 
Apart from the here described newly discovered 
anti-angiogenic effect, human miR-7 was first described 
by Lim et al. in 2003 [28] and later this miRNA was 
found to be associated with anti-tumorigenic effects in 
glioma, hepatocellular carcinoma cells, and head and neck 
cancer cells [29-34]. In these cells anti-tumorogenesis 
is modulated amongst others through direct targeting 
of both the PI3K/Akt pathway and EGFR [29-34]. Our 
observation that miR-7 inhibits proliferation of U-87 MG 
cells confirms the anti-tumorigenic effect of miR-7 in 
tumor cells. 
To elucidate the mechanism of action by which 
miR-7 exerts the anti-angiogenic effects, transcriptional 
analysis of miR-7 mimic transfected HUVEC was 
performed. Pathway analysis of gene expression 
changes implicated, amongst others, suppression of 
neovascularization. Overlay of the miR-7 predicted 
target genes with down-regulated genes with a functional 
annotation in neovascularization led to selection of OGT 
as putative novel target of miR-7. OGT is an enzyme 
that is involved in the hexosamine biosynthetic pathway 
which adds an O-GlcNAc moiety to the free hydroxyl 
group of select serine and threonine residues on a diverse 
population of nuclear and cytosolic proteins [35, 36]. 
Downregulation of OGT in tumor cells leads to increased 
degradation of the oncogenic transcription factor Forkhead 
transcription factor (FoxM1) protein, a direct regulator of 
VEGFR-2 and FoxF1 expression in EC [21, 37]. Here 
we show for the first time that OGT is a target of miR-
7, suggesting that the anti-angiogenic effect of miR-7 in 
EC can, at least partly, be mediated by downregulation of 
OGT. However, inhibition of OGT in EC does not inhibit 
EC tube formation or migration, which indicates that OGT 
is a suitable biomarker for miR-7 activity, but does not 
explain the anti-angiogenic activity of miR-7 in EC. It is 
noted that other miR-7 targets, such as EGFR and PI3K 
were not down-regulated in miR-7 treated EC based on the 
RNA-seq analysis (Supplementary Table S7), suggesting 
that the anti-proliferative activity of miR-7 occurs through 
other pathways in EC than in tumor cells. Investigation 
of gene expression levels of known miR-7 target shows 
that EGFR and PI3K and most of the other known miR-7 
targets are not affected in HUVEC after miR-7 transfection 
(Supplementary Fig S10). The mechanism through which 
miR-7 regulates distinct pathways in EC and tumor cells 
will be subject of future research. 
Not only did miR-7 inhibit growth factor 
induced angiogenesis in vitro but miR-7 also impaired 
developmental angiogenesis in chicken embryo CAM 
with potency comparable to sunitinib. In order to evaluate 
and validate the anti-angiogenic effect of miR-7 mimic in 
vivo, we used a Neuro2A syngeneic tumor model, because 
these tumors are well vascularized and respond well to 
anti-angiogenic therapy [25, 38, 39]. Tumor treatment 
with intratumoral injection of miRNA delivered by 
electroporation showed that the miR-7 mimic decreased 
angiogenesis and reduced tumor growth. Proliferative 
status of tumor cells in the different treatment groups was 
comparable, indicating that the primary mechanism of 
action for the inhibition of tumor growth in this model 
was inhibition of angiogenesis. 
Electroporation has limited clinical application since 
it can only deliver miRNA locally in superficial tumors. 
For broader clinical application, a systemic delivery 
system is needed. We developed a novel αvβ3/αvβ5-
integrin targeted nanoparticles for systemic delivery of 
miR-7 mimic to tumor EC and tumor cells and evaluated 
it in a human glioblastoma xenograft tumor model. 
Indirect evidence for systemic delivery of miR-7 to the 
tumor tissue was provided by the observation that mice 
treated with the miR-7 mimic-loaded, integrin-targeted 
nanoparticles had smaller, pale and less vascularized 
tumors than control mice. The nanoparticles developed in 
the current study might elicit dual activity, as not only the 
EC express high integrin levels, but also in tumor cells. 
This suggests that inhibition of miR-7 mediated tumor 
growth is caused by a combined effect on both tumor 
cells and tumor EC. Indeed, miR-7 inhibits proliferation 
of not only HUVEC, but also of U-87 MG cells in vitro. 
Furthermore, not only tumor vessel density was reduced, 
expression of the nuclear proliferation marker Ki-67 and 
expression of the newly identified miR-7 target gene OGT 
were also affected by miR-7 treatment in vivo. 
The U-87 MG xenograft tumor model was selected 
because it is highly vascularized and responds well to 
anti-angiogenic therapy such as bevacizumab or sunitinib 
[40, 41], making it a suitable model to study the anti-
angiogenic property of miR-7. Naturally, this model does 
not reflect the nature of glioblastomas in the clinic and 
recently it was shown that angiogenesis inhibition in 
glioblastoma patients may induce glioblastoma migration 
and invasion [42, 43]. In this work, the U-87MG model 
was used to explore the feasibility of miR-7 as anti-
angiogenic agent and other therapeutically relevant tumor 
Oncotarget6696www.impactjournals.com/oncotarget
models will be explored in the near future.
The dual targeting of the cRGD-coated nanoparticles 
to both endothelial as well as cancer cells provides 
potential for high therapeutic efficacy of miR-7. Together 
with the well-known role of miR-7 as regulator of invasion 
and migration in cancer, the novel anti-angiogenic 
property of miR-7 and its regulation of diverse genes 
involved in angiogenesis strengthen its potential value as 
therapeutic agent for the treatment of cancer
MATERIAL AND METHODS
Cell Culture and reagents 
Human Umbilical Vein Endothelial Cells 
(HUVEC) (Lonza) were cultured in EBM-2 medium 
(Lonza) supplemented with bullet kit (EGM-2, Lonza) 
containing several growth factors and 10% Fetal Calf 
Serum (FCS) (Sigma). Cells were used between passages 
2 and 7. Immortalized EC (EC-RF24) (ABM#T0003) 
were cultured in M199 medium (Gibco) containing 
FCS (Sigma), Human Serum (HS) (Sigma), 100 U/ml 
Penicillin/Streptavidin (P/S) (Biochrom AG) and 200 nM 
L-glutamin (Sigma). Immortalized murine neuroblastoma 
(Neuro2A, ATCC CCL-131) were cultured in RPMI-
1640 with 10% FCS and antibiotics (100 U/ml Penicillin, 
100 µg/ml Streptomycin, and 0.25 µg/ml amphotericin 
B). Human glioblastoma U-87 MG cells (gift from Prof. 
James A. Mixson, University of Maryland, US) were 
cultured in DMEM containing 10% FCS. 
Stem-loop Reverse Transcription PCR 
RNA isolation was perfomed using Trizol 
(Invitrogen) following the manufacturer′s protocol. The 
presence of miRNA was determined by Stem-Loop RT-
PCR as described in Chen et. al. [44]. mRNA levels were 
determined according to standard protocol using home-
made primers and SYBRGreen (Bio-Rad, CA, USA). 
For the stem-loop RT-PCR individual forwards primers 
were designed according to mature miRNA sequence in 
miRBase 16. The mRNA RT-PCR primers were obtained 
from PrimerBank [45]. As a housekeeping gene U6 was 
used for miRNA and HPRT, GAPDH and/or BGUS were 
used for mRNA. RT-PCR was performed on a BioRad 
CFX96 (CA,USA). Sequences of the primers are described 
in Supplementary Table S5.
Proliferation assay with mature miRNA mimic
HUVEC, seeded in 96-well plate (7500 cells/well), 
were transfected with miRNA mimic using X-tremeGENE 
(Roche) on the following day according to manufacturer’s 
protocol (0.5 µl X-tremeGENE for each 96-well). Mimics 
(Pre-miR™ miRNA Precursors, Ambion) and siRNA PLK-
1 (ON-TARGET plus SMARTpool, Dharmacon) were 
tested at different concentrations. As negative control Pre-
miR™ miRNA Precursor Negative Control #1 (Ambion) 
was used (miR-Scr). Cell viability was determined with 
the MTS assay according to manufacturer′s protocol 
(Promega). 
Tube formation 
HUVEC, seeded in 6-well plate (8x104 cells/
well), were transfected with 50 nM miRNA mimic with 
Lipofectamine 2000 (Invitrogen, UK) on the following 
day according to manufacturer′s protocol in serum free 
medium. After 4 hrs, medium was replaced with EGM-
2. After 48 hrs incubation, a 96-well plate was coated 
with 50 µl MatrigelTM (BD Biosciences, San Jose, CA) 
and incubated for 30 min at 37°C. Transfected HUVEC 
were counted, prepared in a cell suspension in EGM-
2 medium and seeded on top of the MatrigelTM (7500 
cells/well). After 17 hrs incubation wells were imaged 
with a Nikon TE2000 microscope at 10x magnification. 
Tubule formation was quantified by counting the number 
of branching points and measuring the total length of 
capillary tubes in at least three independent wells from the 
same condition using NIH ImageJ software.
Sprouting assay
HUVEC, seeded in a 6-well plate (8x104 cells/
well), were transfected with 50 nM miRNA mimic using 
X-tremeGENE (see above). After 48 hrs cells were 
suspended in culture medium containing 20% (v/v) 
methocell at a final density of 4x104 cells/ml to form 
cell spheroids. Spheroids were embedded in collagen gel 
containing 100ng/ml bFGF (Reliatech, Braunschweich, 
Germany) and allowed to sprout for 16 hrs. Phase-contrast 
images were captured using a Hitachi GiGE camera 
1.4MB, linked to an inverted Leica microscope DMI3000. 
In vitro capillary sprouting was quantified by measuring 
the cumulative sprout length and the number of sprouts 
per spheroid using NIH ImageJ software. 
Migration assay
HUVEC were transfected using Lipofectamine 2000 
(see above). 48 hrs after transfection cells were counted 
and seeded in 24-well plates (6x104 cells/well). Two 
hours after cell seeding a scratch wound was made using 
a yellow pipette tip vertically across each well. Wells 
were washed and medium was refreshed to remove cell 
debris. Images of the wells were taken on a Nikon TE2000 
microscope at T=0, 6 and 17 hrs. 
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Deep sequencing
HUVEC were seeded in a 6-well plate (8x104 cells/
well) and transfected with 15 nM miRNA mimic using 
X-tremeGENE (see above). After 72 hrs, RNA was 
isolated using Trizol (Invitrogen) reagent according to 
manufacturer′s protocol. Purified total RNA concentration 
was measured using a Qbit®Fluormeter and 30 µg total 
RNA was used to create RNA-seq libraries. Isolation of 
mRNA was performed using MicroPoly(A) Purist kit 
(Ambion) and mRNA-ONLY kit (Epicenter). Samples 
were prepared for sequencing using the SOLiD™ Total 
RNA-Seq Kit (Applied Biosystem). Relative expression 
was calculated as the ratio of reads mapping to a gene in 
the miR-7 transfected sample and the reads mapping to a 
gene in the miR-Scr transfected sample.
3′-UTR luciferase assay
The 3′UTR sequences (Supplementary Table S6) 
were synthesized by IDT technologies, and cloned into 
psiCHECKTM-2 (Promega). Hela cells seeded in 24-well 
plated, were co-transfected with 10 nM miR-7 or miR-
Scr and 100ng/well 3′UTR psiCHECKTM-2 construct 
using Lipofectamine 2000 (Invitrogen) according to 
manufacturers protocol. After 48 hrs, cells were lysed 
using Passive Lysis Buffer and luciferase activity was 
measured using the Dual-Luciferase Reporter Assay 
System (Promega) and Glomax-Multi Detection system 
(Promega) in 96-well format according to manufacturer′s 
protocol.
Immunoblotting
HUVEC, seeded in a 6-well plate (8x104 cells/well), 
were transfected at different concentrations of miR-7 using 
X-tremeGENE (see above). After 48 hrs cells were lysed 
in 200 µl radioimmunoprecipitation assay (RIPA) buffer 
(ThermoFisher) containing protease inhibitors (1x) and 
EDTA(1x) for 20 min on ice. Lysates were centrifuged at 
4°C at 13,500 RCF for 15 min to remove the debris. Equal 
amounts of protein were run on SDS-PAGE gels and 
subsequently transferred to nitrocellulose membrane. Blots 
were incubated with primary antibodies OGT (1:1000. 
Cell Signaling) and Beta Actin (1:1000. Cell Signaling) 
followed by peroxidase-conjugated secondary antibody 
(Cell signaling). Bands were visualized with SuperSignal 
West Femto Chemiluminescent substrate (Pierce). Images 
were acquired with Gel Doc XRS imaging system with 
quantity One analysis software (Bio-Rad). All images 
shown are representative of 3 independent experiments. 
Chorio Allantoic Membrane (CAM)-Assay
Fertilized white leghorn chicken eggs were pre-
incubated at 37°C with 45% humidity. After 2 days 2-3 ml 
albumin was removed from the egg in order to detach the 
CAM from the shell. On day 10 after making a window 
in the shell, sterile nitrocellulose rings were placed on top 
of the CAM. Subsequently, the rings were loaded with 
300 picomol miR-Scr or miR-7 mimics complexed with 
Lipofectamine 2000 in 20 mM Hepes buffered glucose 
(pH 7,4). 200 picomol Sunitinib (Sequoia Research 
Products) was used as positive control. On day 10 and 
12 CAMs were photographed in ovo with a Olypmus e40 
camera. 
Neuroblastoma in vivo model: local delivery
The neuroblastoma (Neuro2A) tumor growth 
experiment was a randomized blinded study performed 
under approval of the University of Utrecht animal ethics 
committee. The protocol is adapted from Vader et. al [46]. 
Six to eight weeks old normal male A/J mice (Harlan) 
housed in environmentally controlled rooms, were injected 
subcutaneously in the right flank with 100 µl Neuro2A 
cells (1x107 cells/ml). Tumor sizes were measured daily 
with digital calipers and tumor volume was calculated 
by using the following formula: (width2 x length) x 0.52. 
Treatment started with a tumor volume between 40-70 
mm3 by intratumoral injection of 10 µg of miRNA every 
other day followed by electroporation at a setting of 200V/
cm using an ECM 830 electroporator (BTX) set to deliver 
2x2 pulses at perpendicular angles (n=7 per group) [47]. 
On day 11 mice were sacrificed and the tumors were 
excised. 
Nanoparticle preparation for systemic 
administration in vivo
AparnaBio′s cRGD-targeted biodegradable delivery 
system (cRGD-PPC) was used for systemic delivery of 
microRNA mimics in vivo [48]and Liu et al. (manuscript 
in preparation). miRNA/polymer nanoparticle were 
prepared at room temperature by dissolving miRNA in 
HGB (20 mM HEPES, 5% Glucose, pH 7.1). An equal 
volume of the polymer solution was mixed with miRNA 
solution (final concentration 0.2 mg/ml) to achieve a molar 
ratio of polymer nitrogen to RNA phosphate (N/P ratio) 
of 6. Mixed solutions were then briefly vortexed and left 
for equilibration for 30 min at room temperature to allow 
nanoparticle formation. 
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Glioblastoma xenograft tumor in vivo model: 
systemic delivery
Systemic delivery of miR-7 nanoparticles in 
tumor bearing mice was a randomized, blinded study 
which was performed in an AALAC certified vivarium 
(Biomedical Research Institute, Rockville, MD, USA). 
Five to six weeks old female athymic mice (Athymic 
Nude-Foxn1nu mice (Harlan, Indianapolis, USA) housed 
in environmentally controlled rooms ,were inoculated with 
U-87 MG cells (5x106 cells/ml suspended in 1:1 PBS/
Matrigel) in their right flank. Tumor sizes were measured 
in the same way as described above. Mice were treated by 
intravenous injection every other day with the cRGD-PPC 
nanoparticles containing 60 µg miRNA mimic, or mir-Scr, 
(n=10 mice per group, 3 mg/kg). PBS was used as control. 
One day after the 8th injection mice were sacrificed and the 
tumors were excised. 
Tissue analysis
Mouse tumors were formalin-fixed, paraffin 
embedded and 6 µm sections were cut for immunostaining. 
Sections were deparaffinized in xylene and rehydrated in 
a graded series of alcohol baths, blocked in 5% normal 
goat serum (Dako) and subsequently incubated either with 
rabbit anti-mouse CD31 antibody (1:500)(Santa Cruz), 
with rabbit anti-mouse Ki-67 antibody (1:300)(Abcam), 
or with rabbit anti-mouse OGT antibody (1:500)(Cell 
Signaling). Next, sections were incubated with 0.3% 
H2O2/PBS, followed by polyHRP goat anti-rabbit IgG 
incubation (Bright Vision). Finally, antibody binding was 
visualized with 3,3′-diaminobenzidine (DAB).
Statistical Analysis
All statistical analyses were performed with Prism 
(GraphPad) or Excel (Microsoft). Two-tailed Student′s 
t test or One-Way ANOVA was used to calculate the 
statistical significance. A p-value <0.05 was considered to 
be statistically significant.
ACKNOWLEDGEMENTS
We would like to thank dr. A. James Mixson from 
the University of Maryland for providing materials and 
advice and Hongzue (Betty) Zhang for technical assistance 
for in vitro and in vivo studies at AparnaBio. We also thank 
dr. A.A. van Puijenbroek, dr. W.M. Gommans and dr. S. 
Vidic for their technical support and advice at InteRNA. 
Finally, we thank dr. M.D. Sollewijn Gelpke for his 
assistance in the RNA-seq analysis and dr. G. Dixon and 
dr. I. Schultz for critically reading the manuscript. This 
work was supported by the Dutch Top Institute Pharma 
(project T3-301).
REFERENCES
1. Skalak TC. Angiogenesis and microvascular remodeling: a 
brief history and future roadmap. Microcirculation. 2005; 
12(1):47-58.
2. Folkman J and Shing Y. Angiogenesis. J Biol Chem. 1992; 
267(16):10931-10934.
3. Folkman J. Angiogenesis: an organizing principle for drug 
discovery? Nat Rev Drug Discov. 2007; 6(4):273-286.
4. Folkman J. Tumor angiogenesis: therapeutic implications. 
N Engl J Med. 1971; 285(21):1182-1186.
5. Fakhrejahani E and Toi M. Tumor angiogenesis: pericytes 
and maturation are not to be ignored. J Oncol. 2012; 
2012:261750.
6. Griffioen AW. Therapeutic approaches of angiogenesis 
inhibition: are we tackling the problem at the right level? 
Trends Cardiovasc Med. 2007; 17(5):171-176.
7. Jain RK, Duda DG, Clark JW and Loeffler JS. Lessons from 
phase III clinical trials on anti-VEGF therapy for cancer. 
Nat Clin Pract Oncol. 2006; 3(1):24-40.
8. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer 
A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera 
F, Couture F, Sirzen F and Cassidy J. Bevacizumab in 
combination with oxaliplatin-based chemotherapy as first-
line therapy in metastatic colorectal cancer: a randomized 
phase III study. J Clin Oncol. 2008; 26(12):2013-2019.
9. Azam F, Mehta S and Harris AL. Mechanisms of 
resistance to antiangiogenesis therapy. Eur J Cancer. 2010; 
46(8):1323-1332.
10. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, 
and function. Cell. 2004; 116(2):281-297.
11. Yang WJ, Yang DD, Na SQ, Sandusky GE, Zhang Q and 
Zhao GS. Dicer is required for embryonic angiogenesis 
during mouse development. Journal of Biological 
Chemistry. 2005; 280(10):9330-9335.
12. Chen CZ, Li L, Lodish HF and Bartel DP. MicroRNAs 
modulate hematopoietic lineage differentiation. Science. 
2004; 303(5654):83-86.
13. Wurdinger T, Tannous BA, Saydam O, Skog J, Grau 
S, Soutschek J, Weissleder R, Breakefield XO and 
Krichevsky AM. miR-296 regulates growth factor receptor 
overexpression in angiogenic endothelial cells. Cancer Cell. 
2008; 14(5):382-393.
14. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi 
M, Fischer A, Burchfield J, Fox H, Doebele C, Ohtani K, 
Chavakis E, Potente M, Tjwa M, Urbich C, Zeiher AM and 
Dimmeler S. MicroRNA-92a controls angiogenesis and 
functional recovery of ischemic tissues in mice. Science. 
2009; 324(5935):1710-1713.
15. Anand S, Majeti BK, Acevedo LM, Murphy EA, 
Mukthavaram R, Scheppke L, Huang M, Shields DJ, 
Lindquist JN, Lapinski PE, King PD, Weis SM and Cheresh 
Oncotarget6699www.impactjournals.com/oncotarget
DA. MicroRNA-132-mediated loss of p120RasGAP 
activates the endothelium to facilitate pathological 
angiogenesis. Nat Med. 2010; 16(8):909-914.
16. Urbich C, Kaluza D, Fromel T, Knau A, Bennewitz K, Boon 
RA, Bonauer A, Doebele C, Boeckel JN, Hergenreider 
E, Zeiher AM, Kroll J, Fleming I and Dimmeler S. 
MicroRNA-27a/b controls endothelial cell repulsion and 
angiogenesis by targeting semaphorin 6A. Blood. 2011.
17. van Mil A, Grundmann S, Goumans MJ, Lei Z, 
Oerlemans MI, Jaksani S, Doevendans PA and Sluijter JP. 
MicroRNA-214 inhibits angiogenesis by targeting Quaking 
and reducing angiogenic growth factor release. Cardiovasc 
Res. 2012.
18. Muramatsu F, Kidoya H, Naito H, Sakimoto S and 
Takakura N. microRNA-125b inhibits tube formation of 
blood vessels through translational suppression of VE-
cadherin. Oncogene. 2013; 32(4):414-421.
19. Nicoli S, Standley C, Walker P, Hurlstone A, Fogarty 
KE and Lawson ND. MicroRNA-mediated integration of 
haemodynamics and Vegf signalling during angiogenesis. 
Nature. 2010; 464(7292):1196-1200.
20. Poell JB, van Haastert RJ, Cerisoli F, Bolijn AS, Timmer 
LM, Diosdado-Calvo B, Meijer GA, van Puijenbroek AA, 
Berezikov E, Schaapveld RQ and Cuppen E. Functional 
microRNA screening using a comprehensive lentiviral 
human microRNA expression library. BMC Genomics. 
2011; 12:546.
21. Caldwell SA, Jackson SR, Shahriari KS, Lynch TP, Sethi 
G, Walker S, Vosseller K and Reginato MJ. Nutrient sensor 
O-GlcNAc transferase regulates breast cancer tumorigenesis 
through targeting of the oncogenic transcription factor 
FoxM1. Oncogene. 2010; 29(19):2831-2842.
22. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, 
Vosseller K and Reginato MJ. Critical role of O-Linked 
beta-N-acetylglucosamine transferase in prostate cancer 
invasion, angiogenesis, and metastasis. J Biol Chem. 2012; 
287(14):11070-11081.
23. Konrad RJ, Zhang F, Hale JE, Knierman MD, Becker GW 
and Kudlow JE. Alloxan is an inhibitor of the enzyme 
O-linked N-acetylglucosamine transferase. Biochem 
Biophys Res Commun. 2002; 293(1):207-212.
24. Kim B, Tang Q, Biswas PS, Xu J, Schiffelers RM, Xie 
FY, Ansari AM, Scaria PV, Woodle MC, Lu P and Rouse 
BT. Inhibition of ocular angiogenesis by siRNA targeting 
vascular endothelial growth factor pathway genes: 
therapeutic strategy for herpetic stromal keratitis. Am J 
Pathol. 2004; 165(6):2177-2185.
25. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm 
G, Molema G, Lu PY, Scaria PV and Woodle MC. Cancer 
siRNA therapy by tumor selective delivery with ligand-
targeted sterically stabilized nanoparticle. Nucleic Acids 
Res. 2004; 32(19):e149.
26. Christie RJ, Matsumoto Y, Miyata K, Nomoto T, 
Fukushima S, Osada K, Halnaut J, Pittella F, Kim HJ, 
Nishiyama N and Kataoka K. Targeted polymeric micelles 
for siRNA treatment of experimental cancer by intravenous 
injection. ACS Nano. 2012; 6(6):5174-5189.
27. Desgrosellier JS and Cheresh DA. Integrins in cancer: 
biological implications and therapeutic opportunities. 
Nature reviews Cancer. 2010; 10(1):9-22.
28. Lim LP, Glasner ME, Yekta S, Burge CB and Bartel 
DP. Vertebrate microRNA genes. Science. 2003; 
299(5612):1540.
29. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, 
Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S and 
Purow B. microRNA-7 inhibits the epidermal growth factor 
receptor and the Akt pathway and is down-regulated in 
glioblastoma. Cancer Res. 2008; 68(10):3566-3572.
30. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick 
JS and Leedman PJ. Regulation of Epidermal Growth 
Factor Receptor Signaling in Human Cancer Cells by 
MicroRNA-7. Journal of Biological Chemistry. 2009; 
284(9):5731-5741.
31. Saydam O, Senol O, Wurdinger T, Mizrak A, Ozdener 
GB, Stemmer-Rachamimov AO, Yi M, Stephens RM, 
Krichevsky AM, Saydam N, Brenner GJ and Breakefield 
XO. miRNA-7 attenuation in Schwannoma tumors 
stimulates growth by upregulating three oncogenic 
signaling pathways. Cancer Res. 2011; 71(3):852-861.
32. Fang Y, Xue JL, Shen Q, Chen J and Tian L. MicroRNA-7 
inhibits tumor growth and metastasis by targeting the 
phosphoinositide 3-kinase/Akt pathway in hepatocellular 
carcinoma. Hepatology. 2012; 55(6):1852-1862.
33. Kalinowski FC, Giles KM, Candy PA, Ali A, Ganda C, Epis 
MR, Webster RJ and Leedman PJ. Regulation of Epidermal 
Growth Factor Receptor Signaling and Erlotinib Sensitivity 
in Head and Neck Cancer Cells by miR-7. PLoS One. 2012; 
7(10):e47067.
34. Zhang N, Li X, Wu CW, Dong Y, Cai M, Mok MT, Wang 
H, Chen J, Ng SS, Chen M, Sung JJ and Yu J. microRNA-7 
is a novel inhibitor of YY1 contributing to colorectal 
tumorigenesis. Oncogene. 2012.
35. Issad T and Kuo M. O-GlcNAc modification of 
transcription factors, glucose sensing and glucotoxicity. 
Trends Endocrinol Metab. 2008; 19(10):380-389.
36. Tvaroska I, Kozmon S, Wimmerova M and Koca J. 
Substrate-assisted catalytic mechanism of O-GlcNAc 
transferase discovered by quantum mechanics/molecular 
mechanics investigation. J Am Chem Soc. 2012; 
134(37):15563-15571.
37. Balli D, Zhang Y, Snyder J, Kalinichenko VV and Kalin 
TV. Endothelial cell-specific deletion of transcription factor 
FoxM1 increases urethane-induced lung carcinogenesis. 
Cancer Res. 2011; 71(1):40-50.
38. Svensson A, Azarbayjani F, Backman U, Matsumoto T and 
Christofferson R. Digoxin inhibits neuroblastoma tumor 
growth in mice. Anticancer Res. 2005; 25(1A):207-212.
39. Pirollo KF and Chang EH. Targeted delivery of small 
Oncotarget6700www.impactjournals.com/oncotarget
interfering RNA: approaching effective cancer therapies. 
Cancer Res. 2008; 68(5):1247-1250.
40. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, 
Ji Y and Conrad CA. Tumor invasion after treatment 
of glioblastoma with bevacizumab: radiographic and 
pathologic correlation in humans and mice. Neuro Oncol. 
2010; 12(3):233-242.
41. de Bouard S, Herlin P, Christensen JG, Lemoisson E, 
Gauduchon P, Raymond E and Guillamo JS. Antiangiogenic 
and anti-invasive effects of sunitinib on experimental 
human glioblastoma. Neuro Oncol. 2007; 9(4):412-423.
42. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas 
R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, 
Kesari S and Wen PY. Bevacizumab for recurrent malignant 
gliomas: efficacy, toxicity, and patterns of recurrence. 
Neurology. 2008; 70(10):779-787.
43. Soda Y, Myskiw C, Rommel A and Verma IM. Mechanisms 
of neovascularization and resistance to anti-angiogenic 
therapies in glioblastoma multiforme. J Mol Med (Berl). 
2013; 91(4):439-448.
44. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen 
JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, 
Lao KQ, Livak KJ and Guegler KJ. Real-time quantification 
of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 
2005; 33(20):e179.
45. Spandidos A, Wang X, Wang H and Seed B. PrimerBank: 
a resource of human and mouse PCR primer pairs for gene 
expression detection and quantification. Nucleic Acids Res. 
2010; 38(Database issue):D792-799.
46. Vader P, van der Meel R, Symons MH, Fens MH, Pieters 
E, Wilschut KJ, Storm G, Jarzabek M, Gallagher WM, 
Schiffelers RM and Byrne AT. Examining the role of Rac1 
in tumor angiogenesis and growth: a clinically relevant 
RNAi-mediated approach. Angiogenesis. 2011.
47. Schiffelers RM, Xu J, Storm G, Woodle MC and Scaria 
PV. Effects of treatment with small interfering RNA on 
joint inflammation in mice with collagen-induced arthritis. 
Arthritis Rheum. 2005; 52(4):1314-1318.
48. Chou ST, Leng Q, Scaria P, Kahn JD, Tricoli LJ, Woodle M 
and Mixson AJ. Surface-Modified HK:siRNA Nanoplexes 
with Enhanced Pharmacokinetics and Tumor Growth 
Inhibition. Biomacromolecules. 2013; 14(3):752-760.
